Thrombolytic therapy in acute myocardial infarction
J. Ward Kennedy, MD, MACCa
a Seattle VA Medical Center, Seattle, Washington, USA

View larger version (11K):
[in a new window]
|
Figure 1 Survival analysis of all 533 patients allocated to intracoronary streptokinase or conventional therapy (control). Numbers denote patients at risk at the various intervals after treatment with streptokinase (top) or conventional therapy (below). Follow-up data were complete at three years. From Simoons et al. (7).
|
|
|